Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.70
+0.10 (0.38%)
Feb 11, 2026, 1:30 PM CST
Market Cap6.49B -22.1%
Revenue (ttm)1.28B +12.6%
Net Income127.99M +19.6%
EPS0.57 +18.3%
Shares Out243.04M
PE Ratio47.02
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume61,264
Average Volume152,175
Open26.60
Previous Close26.60
Day's Range26.50 - 26.75
52-Week Range22.30 - 40.20
Beta0.10
RSI50.02
Earnings DateMar 20, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan. [Read more]

Sector Healthcare
Founded 2008
Employees 173
Stock Exchange Taipei Exchange
Ticker Symbol 4166
Full Company Profile

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.

Financial Statements